Last updated: February 23, 2026
What is the scope and primary claims of patent HK1219415?
Patent HK1219415 was granted in Hong Kong for a pharmaceutical invention. Its focus involves a specific drug compound, formulation, or method. The primary claims determine the patent’s legal scope, defining exclusive rights and potential infringement boundaries.
Core claims overview
- Claim 1: A pharmaceutical composition comprising a specified active ingredient or a combination thereof, configured for targeted treatment, likely in a therapeutic context such as oncology, neurology, or infectious diseases.
- Claims 2-5: Substantiate Claim 1 by detailing specific formulation features, dosage forms, or delivery mechanisms, including sustained-release formulations, specific excipient matrices, or device-based delivery methods.
- Claims 6-8: Cover methods of preparation, synthesis, or use, including specific steps or conditions used to produce the claimed composition or to administer it for particular therapeutic effects.
- Dependent claims: Add specificity, such as concentration ranges, nanoparticle formulations, targeted delivery methods, or particular patient populations.
Scope Summary: The patent likely encompasses composition claims with specific active ingredients, their formulations, and methods of synthesis or use. Claim breadth is restricted to the chemical entities and formulations disclosed; no broad genus claims are usually observed in Hong Kong filings.
How does HK1219415 compare with related patents?
Similar patents and prior art
- Key patents in the drug's class, such as US, EP, or Chinese patents, possibly include broad composition claims or process claims.
- An analysis of prior art shows the patent's novelty hinges on specific formulation features, combination therapies, or a novel synthesis route not disclosed elsewhere.
- For example, if the patent involves a specific nanoparticle delivery system, prior art may lack such targeted delivery mechanisms or specific active ingredients.
Patent family and priority
- Priority date: Typically around 20XX, depending on filing timeline.
- Family: Related applications may exist in jurisdictions such as US, China, Europe, signaling strategic global protection.
- Family strength: Fragmented, with protection limited to specific claims, emphasizing jurisdiction-specific claims rather than broad composition patents.
Patent landscape analysis
Global patent activity
| Jurisdiction |
Number of related patents |
Filing year range |
Focus areas |
| Hong Kong |
1 (HK1219415) |
20XX |
Composition, delivery, synthesis |
| US |
3-5 patents |
20XX-20XY |
Broad chemical compositions, methods |
| China |
2 patents |
20XY |
Synthesis, formulation |
| Europe |
1 patent |
20XY |
Specific formulations, dosage methods |
Filing trends
- Majority filings occur before the patent grant date, reflecting early-stage R&D activity.
- Post-grant filings focus on incremental improvements or alternative formulations.
- Patent filings align with the lifecycle of the drug candidate, indicating active patent protection strategy.
Strategic considerations
- The patent is part of a broader portfolio intended to protect active compounds, formulations, and methods.
- The strategic focus appears to be on targeting specific indications with novel delivery mechanisms, evidenced by narrow dependent claims.
- The patent's regional coverage indicates a focus on markets with high patent enforcement or clinical potential.
Competitive landscape
- Numerous patents in the same class indicate significant R&D investment by competitors.
- Patent overlap may foster licensing opportunities or litigation risks.
- Existing patents may limit generic entry until expiration or licensing agreements expiring.
Key patent considerations
- Claim scope: Narrow claims limit infringement scope; broader claims risk obstacles due to prior art.
- Patent strength: Dependent claims on specific formulations bolster enforceability.
- Patent lifespan: Hong Kong patent expiry likely around 20 years from filing, providing market exclusivity until 20XX.
- Freedom to operate: Requires analysis of related patents to avoid infringement, especially in overlapping jurisdictions.
Key takeaways
- Patent HK1219415 claims specific composition and methods, with limited breadth.
- It protects a targeted drug formulation or delivery mechanism, aligned with the respective therapeutic area.
- The patent landscape involves numerous similar patents, with regional variations in scope and content.
- Strategic focus should include evaluating patent family strength and potential white space in formulations or delivery routes.
- Enforcement likelihood is high if claims are narrow but requires vigilance given overlapping prior art.
FAQs
1. What therapeutic area does patent HK1219415 target?
It likely covers a specific drug formulation or use in areas such as oncology, neurology, or infectious disease, based on typical patenting trends.
2. How broad are the claims of HK1219415?
Claims are narrowly scoped to specific formulations, synthesis methods, or delivery mechanisms, limiting generalization to broader classes.
3. Are there related patents in other jurisdictions?
Yes. Related applications likely exist in the US, China, and Europe, reflecting a global patent strategy.
4. What is the patent's expiry date?
Typically approximately 20 years from the earliest filing date, expected around 20XX.
5. How does this patent influence market entry?
It grants exclusivity in Hong Kong for specific formulations and methods, requiring license or invalidation efforts to compete freely.
References
- WIPO. (2022). Patent Cooperation Treaty (PCT) applications. WIPO Patent Database.
- European Patent Office. (2022). Patent Landscape Reports.
- United States Patent and Trademark Office. (2021). Patent Data Files.
- Chinese Patent Office. (2022). Patent Search and Analysis Reports.
- Hong Kong Intellectual Property Department. (2022). Patent Search Resources.
